Paulo Carita

Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease

Andrew Palmer, Lieven Annemans, Stéphane Roze et al. · Diabetes Care · 2004 · 93 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +16

Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the 'Perception of Anticoagulant Treatment Questionnaire' (PACT-Q©)

Martin H. Prins, Alexia Marrel, Paulo Carita et al. · Health and Quality of Life Outcomes · 2009 · 58 citations · Full text

Medicine, Cardiology, Pharmacology +14

Cost Minimization Analysis of Antiepileptic Drugs in Newly Diagnosed Epilepsy in 12 European Countries

Dominic Heaney, Simon Shorvon, Josemir W. Sander et al. · Epilepsia · 2000 · 50 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Alzheimer’s Disease Severity is Not Significantly Associated with Short Sleep: Survey by Actigraphy on 208 Mild and Moderate Alzheimer’s Disease Patients

Damien Léger, Alexandre Dubois, Stéphane Rio et al. · Journal of Alzheimer s Disease · 2016 · 21 citations

Medicine, Geriatric Medicine, Neurology +17

Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria

Andrew Palmer, Lieven Annemans, Stéphane Roze et al. · Kidney International · 2004 · 20 citations · Full text

Pharmacy, Internal Medicine, Pharmacoeconomics +11